Articles Related to Bone Marrow
A Chronic Myeloid Leukemia Case Showing Spontaneous Ph-positive Clone Regression and Bone Marrow Hypoplasia after a Short Treatment with Dasatinib
Dasatinib is an orally bioavailable second generation TKI, more potent than imatinib. Bone marrow aplasia or hypoplasia secondary to TKI therapy is an uncommon adverse event. We report here the first case of chronic myeloid leukemia in chronic phase shortly treated with dasatinib that developed a prolonged bone marrow hypoplasia with concomitant response on the hematological disease with gradual improvement of the cytogenetic and molecular response after dasatinib discontinuation, without use of any other TKI therapy.
Severe Bone Marrow Suppression Associated with Use of Clopidogrel
A 60 year-old male presented with fever, malaise, and myalgias. The patient was admitted 3 weeks prior for acute coronary syndrome, underwent coronary stent placement, and was started on clopidogrel.
Responses and Survival under Pegylated Interferon α2a Treatment for Patients with Post-MPN Acute Myeloid Leukemia and Acute Panmyelosis with Myelofibrosis
We report here for the first time the efficacy of pegylated interferon α2a (Peg-Ifn) as a therapy for patients with myelofibrosis and high blast counts. We treated four patients who were in an accelerated phase of myeloproliferative neoplasms or acute panmyelosis with myelofibrosis using only this drug.
Mesenchymal Stem Cells from Different Tissues: Immune Status and Activity
Mesenchymal stem cells (MSCs) have been found in almost all tissues and due to their regenerative properties represent promising tools in cell-based therapy. Role of MSCs in tissue repair is strongly governed by their interplay with immune cells and regulating factors.
Mesenchymal Stem Cells in the Treatment of Patients with Chronic Spinal Cord Injury (ASIA A) with Residual Electrophysiological Function
Bone-marrow derived mesenchymal stem cells (MSC) represent an experimental form of therapy in the treatment of chronic spinal cord injury (SCI), up to two years after trauma.
Sarcoidosis - A Case of “Resistant Tuberculosis”
Sarcoidosis is a multisystem granulomatous disease of unknown aetiology. It usually has a benign course, but those cases with multi system involvement have poorer prognosis. Sarcoidosis is an under diagnosed disease in India, probably due to the close resemblance to tuberculosis and the lack of awareness. But this disease is not so rare in India, as previously thought.
Microfilaria Causing Bone Marrow Failure
It is common to detect microfilariae in various cytological preparations, however there are very few case reports describing microfilariae in bone marrow aspirates. It is rarer to get bone marrow failure secondary to microfilaria in bone marrow. We report here a patient from Bihar, presented to us with prolonged fever and pancytopenia, bone marrow aspirate showed microfilaria. Treatment with DEC and albendazole resulted in prompt recovery.
Parenteral Nutrition Utilization in Bone Marrow Transplant Recipients
Bone marrow transplant (BMT) recipients often require parenteral nutrition (PN) to meet their nutrient needs. While general guidelines
for the provision of PN support by nutrition support teams (NSTs) have been shown to decrease inappropriate PN use, recommendations
for nutrition in BMT recipients are lacking.
Anti-Inflammatory and Anti-Arthritic Efficacy and Safety of Purified Shilajit in Moderately Arthritic Dogs
The objective of this investigation was to evaluate the efficacy and safety of purified Shilajit in moderately arthritic dogs. Ten client-owned dogs in a randomized double-blinded study received either a placebo or Shilajit (500 mg) twice daily for a period of five months. Dogs were evaluated each month for physical condition (body weight, body temperature, heart rate, and respiration rate) and pain associated with arthritis (overall pain, pain from limb manipulation, and pain after physical exertion).
Editorial Board Members Related to Bone Marrow
Paulo Nunes Costa Filho
School of Physical Education and Sports, Rio de Janeiro Federal University, Av. Carlos Chagas Filho, 540 - Cidade Universitária, Rio de Janeiro, RJ, 21940-901, Brazil.
Jonathan R. Keller
Principal Investigator
Hematopoiesis and Stem Cell Biology Section
Center for Cancer Research
National Cancer Institute
United States
Hematopoiesis and Stem Cell Biology Section
Center for Cancer Research
National Cancer Institute
United States
